Psychological and Biological Changes Observed in The Mind of Patients with Alzheimer’s Disease
Keywords:
Neurodegeneration, amyloid plaques, cognitive decline, brain atrophy, behavioral changes, dementia, biomarkers, emotional changes.Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and significant psychological changes, making it one of the most common causes of dementia in older adults. Affecting millions worldwide, AD poses a profound impact on both patients and their families. This paper explores the dual dimensions of Alzheimer’s disease: the biological changes in the brain and the psychological alterations experienced by patients. Biologically, AD is marked by the buildup of amyloid-beta plaques and tau protein tangles, leading to neuronal death and brain atrophy, particularly in regions responsible for memory and executive functions. These structural changes in the brain correlate with a gradual decline in mental faculties, manifested in memory loss, impaired judgment, and disorientation. Psychologically, Alzheimer’s patients undergo emotional and behavioral shifts that can include depression, anxiety, agitation, and hallucinations, affecting their overall quality of life and social relationships. These psychological changes often exacerbate as the disease progresses, transforming not only the patient’s cognitive state but also their personality and emotional well-being. Research has shown that biological changes in the brain contribute directly to these psychological symptoms, revealing a complex interplay between molecular and psychological processes. Advances in neuroimaging and biomarker studies have improved the understanding of AD pathology, yet effective treatments remain limited.
References
CR Jack, VJ Lowe, SD Weigand, HJ Wiste, ML Senjem, DS Knopman, et al. Serial PiB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain. 132: 2009; 1355–1365
National Institutes of Health. National Institute on Aging. What happens to the Brain in Alzheimer's Disease?, Available at: https://www.nia.nih.gov/health/what-happens-brainalzheimers-disease Accessed September 14, 2018
Mayo Clinic. Alzheimer’s disease – causes and symptoms. Available at: https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447
RA Sperling, PS Aisen, LA Beckett, DA Bennett, S Craft, AM Fagan, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7: 2011; 280–292
R. Katzman. The prevalence and malignancy of Alzheimer disease: A major killer. Arch Neurol (1976)
W.W. Barker et al. Relative frequencies of Alzheimer's disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord(2002) 7. Karimovna, N. Y. (2022). Autism and the importance of communication with patients of this disease. Gospodarka i Innowacje., 23, 8-10. 8. Нарметова, Ю. (2015). Методологические и методические проблемы организации психологической службы в медицинских учреждениях. 9. Narmetova, Y. (2024). COMPARATIVE ANALYSIS OF THE PSYCHOLOGICAL STATE AND SOCIO-PSYCHOLOGICAL CHARACTERISTICS OF PATIENTS WITH PSYCHOSOMATIC DISEASES. Current approaches and new research in modern sciences, 3(3), 83-87. 10. Karimovna, N. Y., Nasirovna, M. R., Tursunaliyevna, A. M., Abduvaliyevna, A. N., & Ravshanovna, U. S. (2023). Psychodiagnostics of psychosomatic diseases. Journal of survey in fisheries sciences, 10(2S), 2903-2911. 11. Karimovna, N. Y., Khasanboy, A., Iltifotkhon, A., Khabiba, N., & Adiba, M. (2023). Psychoemotional characteristics in psychosomatic diseases. The Scientific Temper, 14(04), 1444-1450.
